BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 20200556)

  • 21. Reduced or absent cyclin H expression is an independent prognostic marker for poor outcome in diffuse large B-cell lymphoma.
    Bavi P; Abubaker J; Hussain A; Sultana M; Al-Dayel F; Uddin S; Al-Kuraya KS
    Hum Pathol; 2008 Jun; 39(6):885-94. PubMed ID: 18400256
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Depletion of the colonic epithelial precursor cell compartment upon conditional activation of the hedgehog pathway.
    van Dop WA; Uhmann A; Wijgerde M; Sleddens-Linkels E; Heijmans J; Offerhaus GJ; van den Bergh Weerman MA; Boeckxstaens GE; Hommes DW; Hardwick JC; Hahn H; van den Brink GR
    Gastroenterology; 2009 Jun; 136(7):2195-2203.e1-7. PubMed ID: 19272384
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinicopathologic significance of immunophenotypic profiles related to germinal center and activation B-cell differentiation in diffuse large B-cell lymphoma from Chinese patients.
    Liu YH; Xu FP; Zhuang HG; Lai KC; Xie D; Luo DL; Li L; Luo XL; Xu J; Zhang MH; Zhang F; Li HM
    Hum Pathol; 2008 Jun; 39(6):875-84. PubMed ID: 18440593
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The hedgehog signaling pathway in the mouse ovary.
    Russell MC; Cowan RG; Harman RM; Walker AL; Quirk SM
    Biol Reprod; 2007 Aug; 77(2):226-36. PubMed ID: 17392501
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Inhibition of the intrinsic apoptosis pathway downstream of caspase-9 activation causes chemotherapy resistance in diffuse large B-cell lymphoma.
    Cillessen SA; Hess CJ; Hooijberg E; Castricum KC; Kortman P; Denkers F; Vos W; van de Wiel MA; Schuurhuis GJ; Ossenkoppele GJ; Meijer CJ; Oudejans JJ
    Clin Cancer Res; 2007 Dec; 13(23):7012-21. PubMed ID: 18056177
    [TBL] [Abstract][Full Text] [Related]  

  • 26. BAL1/ARTD9 represses the anti-proliferative and pro-apoptotic IFNγ-STAT1-IRF1-p53 axis in diffuse large B-cell lymphoma.
    Camicia R; Bachmann SB; Winkler HC; Beer M; Tinguely M; Haralambieva E; Hassa PO
    J Cell Sci; 2013 May; 126(Pt 9):1969-80. PubMed ID: 23487038
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Loss of B-cell receptor expression defines a subset of diffuse large B-cell lymphoma characterized by silent BCR/PI3K/AKT signaling and a germinal center phenotype displaying low-risk clinicopathologic features.
    Wang WG; Cui WL; Wang L; Zhu F; Wan XC; Ping B; Zhou XY; Li XQ
    Am J Surg Pathol; 2015 Jul; 39(7):902-11. PubMed ID: 25970684
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Distinct IL-4-induced gene expression, proliferation, and intracellular signaling in germinal center B-cell-like and activated B-cell-like diffuse large-cell lymphomas.
    Lu X; Nechushtan H; Ding F; Rosado MF; Singal R; Alizadeh AA; Lossos IS
    Blood; 2005 Apr; 105(7):2924-32. PubMed ID: 15591113
    [TBL] [Abstract][Full Text] [Related]  

  • 29. IL10 receptor is a novel therapeutic target in DLBCLs.
    Béguelin W; Sawh S; Chambwe N; Chan FC; Jiang Y; Choo JW; Scott DW; Chalmers A; Geng H; Tsikitas L; Tam W; Bhagat G; Gascoyne RD; Shaknovich R
    Leukemia; 2015 Aug; 29(8):1684-94. PubMed ID: 25733167
    [TBL] [Abstract][Full Text] [Related]  

  • 30. LKB1 suppresses proliferation and invasion of prostate cancer through hedgehog signaling pathway.
    Xu P; Cai F; Liu X; Guo L
    Int J Clin Exp Pathol; 2014; 7(12):8480-8. PubMed ID: 25674212
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Identification of Ezrin-Radixin-Moesin proteins as novel regulators of pathogenic B-cell receptor signaling and tumor growth in diffuse large B-cell lymphoma.
    Pore D; Bodo J; Danda A; Yan D; Phillips JG; Lindner D; Hill BT; Smith MR; Hsi ED; Gupta N
    Leukemia; 2015 Sep; 29(9):1857-67. PubMed ID: 25801911
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Rewired NFκB signaling as a potentially actionable feature of activated B-cell-like diffuse large B-cell lymphoma.
    Knittel G; Liedgens P; Korovkina D; Pallasch CP; Reinhardt HC
    Eur J Haematol; 2016 Dec; 97(6):499-510. PubMed ID: 27526684
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Overexpression of heme oxygenase-1 induced by constitutively activated NF-κB as a potential therapeutic target for activated B-cell-like diffuse large B-cell lymphoma.
    Huang J; Guo P; Ma D; Lin X; Fang Q; Wang J
    Int J Oncol; 2016 Jul; 49(1):253-64. PubMed ID: 27211510
    [TBL] [Abstract][Full Text] [Related]  

  • 34. MCL1 is deregulated in subgroups of diffuse large B-cell lymphoma.
    Wenzel SS; Grau M; Mavis C; Hailfinger S; Wolf A; Madle H; Deeb G; Dörken B; Thome M; Lenz P; Dirnhofer S; Hernandez-Ilizaliturri FJ; Tzankov A; Lenz G
    Leukemia; 2013 Jun; 27(6):1381-90. PubMed ID: 23257783
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Complementary IL-23 and IL-27 anti-tumor activities cause strong inhibition of human follicular and diffuse large B-cell lymphoma growth in vivo.
    Cocco C; Di Carlo E; Zupo S; Canale S; Zorzoli A; Ribatti D; Morandi F; Ognio E; Airoldi I
    Leukemia; 2012 Jun; 26(6):1365-74. PubMed ID: 22193967
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Gambogic acid induces apoptosis in diffuse large B-cell lymphoma cells via inducing proteasome inhibition.
    Shi X; Lan X; Chen X; Zhao C; Li X; Liu S; Huang H; Liu N; Zang D; Liao Y; Zhang P; Wang X; Liu J
    Sci Rep; 2015 Apr; 5():9694. PubMed ID: 25853502
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Inhibition of COP9-signalosome (CSN) deneddylating activity and tumor growth of diffuse large B-cell lymphomas by doxycycline.
    Pulvino M; Chen L; Oleksyn D; Li J; Compitello G; Rossi R; Spence S; Balakrishnan V; Jordan C; Poligone B; Casulo C; Burack R; Shapiro JL; Bernstein S; Friedberg JW; Deshaies RJ; Land H; Zhao J
    Oncotarget; 2015 Jun; 6(17):14796-813. PubMed ID: 26142707
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Constitutively activated STAT3 promotes cell proliferation and survival in the activated B-cell subtype of diffuse large B-cell lymphomas.
    Ding BB; Yu JJ; Yu RY; Mendez LM; Shaknovich R; Zhang Y; Cattoretti G; Ye BH
    Blood; 2008 Feb; 111(3):1515-23. PubMed ID: 17951530
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacologic inhibition of MALT1 protease by phenothiazines as a therapeutic approach for the treatment of aggressive ABC-DLBCL.
    Nagel D; Spranger S; Vincendeau M; Grau M; Raffegerst S; Kloo B; Hlahla D; Neuenschwander M; Peter von Kries J; Hadian K; Dörken B; Lenz P; Lenz G; Schendel DJ; Krappmann D
    Cancer Cell; 2012 Dec; 22(6):825-37. PubMed ID: 23238017
    [TBL] [Abstract][Full Text] [Related]  

  • 40. PRMT5 is upregulated by B-cell receptor signaling and forms a positive-feedback loop with PI3K/AKT in lymphoma cells.
    Zhu F; Guo H; Bates PD; Zhang S; Zhang H; Nomie KJ; Li Y; Lu L; Seibold KR; Wang F; Rumball I; Cameron H; Hoang NM; Yang DT; Xu W; Zhang L; Wang M; Capitini CM; Rui L
    Leukemia; 2019 Dec; 33(12):2898-2911. PubMed ID: 31123343
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.